| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIAB.38.9.1165 |
| P698 | PubMed publication ID | 2670645 |
| P2093 | author name string | Dunaif A | |
| Futterweit W | |||
| Dobrjansky A | |||
| Segal KR | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| polycystic ovary syndrome | Q500816 | ||
| insulin resistance | Q1053470 | ||
| polycystic ovary | Q5547896 | ||
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 1165-1174 | |
| P577 | publication date | 1989-09-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome | |
| P478 | volume | 38 |
| Q33750447 | A cross-sectional study of polycystic ovarian syndrome among adolescent and young girls in Mumbai, India |
| Q46154092 | Acupuncture and exercise restore adipose tissue expression of sympathetic markers and improve ovarian morphology in rats with dihydrotestosterone-induced PCOS. |
| Q37879616 | Acupuncture for infertility: is it an effective therapy? |
| Q30411308 | Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial |
| Q37348872 | Adipocytes from women with polycystic ovary syndrome demonstrate altered phosphorylation and activity of glycogen synthase kinase 3. |
| Q36058331 | Adiponectin in women with polycystic ovary syndrome |
| Q36593148 | Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. |
| Q33587839 | Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis |
| Q64107820 | Afamin predicts gestational diabetes in polycystic ovary syndrome patients preconceptionally |
| Q34227276 | Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. |
| Q43627681 | Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome |
| Q43441552 | Alterations in thyroid function among the different polycystic ovary syndrome phenotypes. |
| Q36334951 | Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome |
| Q99638779 | Altered m6 A modification is involved in up-regulated expression of FOXO3 in luteinized granulosa cells of non-obese polycystic ovary syndrome patients |
| Q58822197 | Androgen excess in pancreatic β cells and neurons predisposes female mice to type 2 diabetes |
| Q33619148 | Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice |
| Q55954238 | Androgens and Therapeutic Aspects of Antiandrogens in Women |
| Q37095103 | Anthropometric characteristics and dietary pattern of women with polycystic ovary syndrome |
| Q46288861 | Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels |
| Q30405604 | Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents |
| Q60309675 | Anti-Müllerian Hormone as a Diagnostic Marker in Egyptian Infertile Polycystic Ovary Syndrome Females: Correlations with Vitamin D, Total Testosterone, Dyslipidemia and Anthropometric Parameters |
| Q52212892 | Are circulating leptin and luteinizing hormone synchronized in patients with polycystic ovary syndrome? |
| Q87369153 | Assessment of atrial conduction time in patients with polycystic ovary syndrome |
| Q43774505 | Assessment of atrial electromechanical delay in patients with polycystic ovary syndrome in both lean and obese subjects |
| Q30429162 | Assessment of insulin resistance and impaired glucose tolerance in lean women with polycystic ovary syndrome |
| Q46574876 | Assessment of insulin resistance in young women with polycystic ovary syndrome |
| Q36582140 | Association between Metabolic Syndrome and Menstrual Irregularity in Middle-Aged Korean Women |
| Q84449805 | Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with polycystic ovary syndrome: a meta-analysis |
| Q45764434 | Association of anthropometric, androgenic and insulin-related features with polymorphisms in exon 8 of SHBG gene in women with polycystic ovary syndrome |
| Q56514154 | Association of anti-Mullerian hormone and small-dense low-density lipoprotein cholesterol with hepatosteatosis in young lean women with and without polycystic ovary syndrome |
| Q37133808 | Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical-biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study |
| Q45917076 | Association of polycystic ovary syndrome with cardiovascular risk factors. |
| Q41116375 | Association of polycystic ovary syndrome with metabolic syndrome and gestational diabetes: Aggravated complication of pregnancy |
| Q77694124 | Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options? |
| Q87944985 | Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women with Polycystic Ovary Syndrome (PCOS) |
| Q93109075 | Barriers and Facilitators to the Implementation of Evidence-Based Lifestyle Management in Polycystic Ovary Syndrome: A Narrative Review |
| Q45942703 | Beta cell function and insulin sensitivity in women with polycystic ovary syndrome: influence of the family history of type 2 diabetes mellitus. |
| Q39833069 | Biochemical factors governing the steady-state estrone/estradiol ratios catalyzed by human 17beta-hydroxysteroid dehydrogenases types 1 and 2 in HEK-293 cells |
| Q50628402 | Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity. |
| Q47386555 | Birth weight in offspring of mothers with polycystic ovarian syndrome |
| Q37703877 | Body Image, Self-Esteem and Depressive Symptomatology in Women with Polycystic Ovary Syndrome |
| Q51298811 | Body fat distribution and its associated factors in Korean women with polycystic ovary syndrome. |
| Q43934268 | Body fat distribution, insulin sensitivity, ovarian dysfunction and serum lipoproteins in patients with polycystic ovary syndrome |
| Q36839553 | Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls |
| Q42458930 | Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. |
| Q72920364 | Bone mineral density in hyperandrogenic amenorrhoea |
| Q37355732 | Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects |
| Q37625979 | C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients? |
| Q37437244 | C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome |
| Q46066344 | Calpain 10 gene single-nucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. |
| Q51581819 | Can metformin reduce insulin resistance in polycystic ovary syndrome? |
| Q34258486 | Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gai |
| Q50056959 | Cardiometabolic Risk in PCOS: More than a Reproductive Disorder |
| Q36287892 | Cardiometabolic aspects of the polycystic ovary syndrome. |
| Q37077315 | Cardiometabolic features of polycystic ovary syndrome |
| Q38645883 | Cardiovascular RiskprofilE - IMaging and gender-specific disOrders (CREw-IMAGO): rationale and design of a multicenter cohort study |
| Q35588340 | Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) |
| Q37031065 | Carotid body denervation prevents the development of insulin resistance and hypertension induced by hypercaloric diets |
| Q112285355 | Changes in Serum Cytokines Throughout Pregnancy in Women With Polycystic Ovary Syndrome |
| Q47287622 | Changes in circulating insulin and corticosterone concentrations during different reproductive phases and their relationships to body weight and androstenedione concentration of male Scotophilus heathi |
| Q39209037 | Chinese Herbal Medicine for the Optimal Management of Polycystic Ovary Syndrome |
| Q47284626 | Chronic combined hyperandrogenemia and western-style diet in young female rhesus macaques causes greater metabolic impairments compared to either treatment alone |
| Q42443274 | Chronic-intermittent cold stress in rats induces selective ovarian insulin resistance |
| Q47108186 | Circulating betatrophin is associated with insulin resistance in humans: cross-sectional and interventional studies in vivo and in vitro |
| Q89339297 | Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome |
| Q26782559 | Clinical characteristics in Taiwanese women with polycystic ovary syndrome |
| Q36862181 | Clinical characteristics of polycystic ovary syndrome in Indian women |
| Q37251943 | Clinical spectrum of premature pubarche: links to metabolic syndrome and ovarian hyperandrogenism |
| Q43165523 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial |
| Q80832590 | Clomiphene citrate: an old favourite lives on |
| Q36080057 | Combined oral contraceptives in the treatment of polycystic ovary syndrome |
| Q48018526 | Combined somatostatin analog and follicle-stimulating hormone for women with polycystic ovary syndrome resistant to conventional treatment |
| Q38776405 | Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome |
| Q50880377 | Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome. |
| Q37482755 | Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. |
| Q92270000 | Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force |
| Q28386403 | Contributions of the Nurses' Health Studies to Reproductive Health Research |
| Q39953031 | Correlation of serum fructosamine and recurrent pregnancy loss: Case-control study |
| Q37939291 | Current perspectives of insulin resistance and polycystic ovary syndrome |
| Q90801248 | Curtailing PCOS |
| Q33760549 | Decreased cord blood estradiol levels in related to mothers with gestational diabetes |
| Q43664600 | Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). |
| Q43820575 | Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria |
| Q44469056 | Diabetes Mellitus Associated with Late Onset Congenital Adrenal Hyperplasia: Coincidence or Causality? |
| Q36738658 | Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study). |
| Q41563034 | Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention |
| Q33587845 | Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline |
| Q36690960 | Diagnostic criteria for polycystic ovarian syndrome |
| Q35749412 | Diet-induced obesity exacerbates metabolic and behavioral effects of polycystic ovary syndrome in a rodent model |
| Q44936296 | Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome |
| Q36950689 | Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation |
| Q72616055 | Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women |
| Q51356567 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. |
| Q24594995 | Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility |
| Q35597070 | Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome |
| Q26766685 | EJE PRIZE 2015: How does insulin resistance arise, and how does it cause disease? Human genetic lessons |
| Q35560531 | Effect Of G2706A and G1051A polymorphisms of the ABCA1 gene on the lipid, oxidative stress and homocystein levels in Turkish patients with polycystıc ovary syndrome |
| Q22242102 | Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial |
| Q37719333 | Effect of exercise intensity on weight changes and sexual hormones (androstenedione and free testosterone) in female rats with estradiol valerate-induced PCOS. |
| Q26991523 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis |
| Q36022491 | Effect of metformin on serum ferritin level in women with polycystic ovary syndrome |
| Q36732072 | Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion |
| Q28073603 | Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials |
| Q42510646 | Effects of androstenedione, insulin and luteinizing hormone on steroidogenesis in human granulosa luteal cells |
| Q50976939 | Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. |
| Q37307972 | Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome |
| Q55883477 | Effects of gonadal androgens and oestrogens on adrenal androgen levels |
| Q30389395 | Effects of hyperandrogenemia and increased adiposity on reproductive and metabolic parameters in young adult female monkeys |
| Q37256835 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis |
| Q51771105 | Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients. |
| Q34674162 | Effects of seasonal adiposity on ovarian activity of Vespertilionid bat, Scotophilus heathi: proteomics analysis |
| Q35497969 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment |
| Q51559289 | Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. |
| Q47549460 | Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats. |
| Q30422591 | Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome |
| Q42481258 | Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia. |
| Q46963140 | Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study |
| Q64286442 | Endocrine implications of bariatric surgery: a review on the intersection between incretins, bone, and sex hormones |
| Q34658641 | Epidemiology, diagnosis, and management of polycystic ovary syndrome |
| Q57134369 | Estrogen Receptor 1 (ESR1) Enhances /GLUT4 Expression by a SP1 Cooperative Mechanism |
| Q72370860 | Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome |
| Q35099918 | Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment |
| Q46632340 | Evaluation of insulin sensitivity in patients with Klinefelter's syndrome: a hyperinsulinemic euglycemic clamp study |
| Q34620242 | Evidence of mononuclear cell preactivation in the fasting state in polycystic ovary syndrome |
| Q34354008 | Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity |
| Q38007200 | Evidence-based lifestyle and pharmacological management of infertility in women with polycystic ovary syndrome |
| Q92325270 | Evolutionary origins of polycystic ovary syndrome: An environmental mismatch disorder |
| Q53739623 | Exaggerated glucagon responses to hypoglycemia in women with polycystic ovary syndrome. |
| Q38420503 | Excess mortality in mothers of patients with polycystic ovary syndrome |
| Q34342999 | Excess of nerve growth factor in the ovary causes a polycystic ovary-like syndrome in mice, which closely resembles both reproductive and metabolic aspects of the human syndrome |
| Q35752347 | Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome |
| Q98177441 | Exercise Interventions in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis |
| Q64237430 | Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis |
| Q39051442 | Expression and clinical significance of the HIF-1a/ET-2 signaling pathway during the development and treatment of polycystic ovary syndrome |
| Q84484303 | Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome |
| Q44593820 | Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome |
| Q37663309 | Female Gender Scheme is Disturbed by Polycystic Ovary Syndrome: A Qualitative Study From Iran |
| Q38332049 | Female-specific factors for IHD: across the reproductive lifespan |
| Q36378559 | Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome |
| Q43101349 | Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters |
| Q58035808 | Genetic Disorders of Insulin Action: Far More than Diabetes |
| Q26745164 | Genetic Rodent Models of Obesity-Associated Ovarian Dysfunction and Subfertility: Insights into Polycystic Ovary Syndrome |
| Q39647079 | Genetic variations in the 3'-untranslated region of SLC18A2 are associated with serum FSH concentration in polycystic ovary syndrome patients and regulate gene expression in vitro |
| Q35178218 | Genetics in endocrinology: genetic forms of severe insulin resistance: what endocrinologists should know |
| Q33792142 | Genetics of polycystic ovary syndrome |
| Q82245844 | Genetics of polycystic ovary syndrome |
| Q36182579 | Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth |
| Q64242278 | Gestational diabetes mellitus and macrosomia predispose to diabetes in the Lebanese population |
| Q37310914 | Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism |
| Q54157028 | Growth hormone, insulin-like growth factor-I axis, and insulin secretion in hyperandrogenic adolescents |
| Q44459107 | Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo. |
| Q33792016 | Heart rate variability in normal-weight patients with polycystic ovary syndrome |
| Q55095950 | High-Fat, High-Sugar Diet Disrupts the Preovulatory Hormone Surge and Induces Cystic Ovaries in Cycling Female Rats. |
| Q45052801 | High-fat high-sugar diet induces polycystic ovary syndrome in a rodent model. |
| Q45909467 | High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS). |
| Q59884613 | How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome? |
| Q64263615 | How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models |
| Q46755958 | How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women |
| Q45974242 | Hyperandrogenemia Induced by Letrozole Treatment of Pubertal Female Mice Results in Hyperinsulinemia Prior to Weight Gain and Insulin Resistance. |
| Q37630561 | Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome |
| Q40572171 | Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus |
| Q42733124 | Hyperandrogenism Accompanies Increased Intra-Abdominal Fat Storage in Normal Weight Polycystic Ovary Syndrome Women |
| Q33569067 | Hyperandrogenism induces a proinflammatory TNFα response to glucose ingestion in a receptor-dependent fashion |
| Q36408593 | Hyperglycemia-induced oxidative stress is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome |
| Q50947769 | Hyperinsulinemia and Decreased Insulin-Like Growth Factor-Binding Protein-1 Are Common Features in Prepubertal and Pubertal Girls with a History of Premature Pubarche1 |
| Q43655172 | Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats |
| Q42490428 | Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors. |
| Q50992930 | Hyperinsulinemia in the polycystic ovary syndrome: a clinical, endocrine and echographic study in 240 patients. |
| Q71828173 | Hyperinsulinemia is common in family members of women with polycystic ovary syndrome |
| Q85942021 | Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance |
| Q53790585 | IL-1 receptor antagonist levels are associated with glucose tolerance in polycystic ovary syndrome. |
| Q35810003 | Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis |
| Q42468073 | Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome |
| Q36964889 | Impact of obstructive sleep apnea on insulin resistance and glucose tolerance in women with polycystic ovary syndrome |
| Q24646187 | Impact of treatment with rosiglitazone or metformin on biomarkers for insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome |
| Q42454010 | Impaired beta-cell compensation to dexamethasone-induced hyperglycemia in women with polycystic ovary syndrome |
| Q34380439 | Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome |
| Q34099068 | Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis |
| Q97422028 | Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome |
| Q37376912 | Imprinting of female offspring with testosterone results in insulin resistance and changes in body fat distribution at adult age in rats |
| Q51631005 | Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. |
| Q52571999 | Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk. |
| Q72067311 | Increased insulin secretion in patients with multifollicular and polycystic ovaries and its impact on ovulation induction |
| Q51380127 | Independent predictors of cardiovascular risk in polycystic ovarian syndrome. |
| Q37523568 | Indexes of Insulin Resistance in Hyperinsulinemic Polycystic Ovary Syndrome in a Macedonian Cohort of Women of Reproductive Age: A Cross-Sectional Study |
| Q36361383 | Inflammation in response to glucose ingestion is independent of excess abdominal adiposity in normal-weight women with polycystic ovary syndrome |
| Q28077261 | Inositol Treatment and ART Outcomes in Women with PCOS |
| Q54117527 | Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. |
| Q41631160 | Insulin and insulin-like growth factor-I responsiveness in polycystic ovarian syndrome. |
| Q54118805 | Insulin and polycystic ovary syndrome: a new look at an old subject. |
| Q34028472 | Insulin and the vasculature |
| Q36928817 | Insulin as an effector of human ovarian and adrenal steroid metabolism. |
| Q35140103 | Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index |
| Q37032897 | Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: Comparison between obese and non-obese PCOS patients |
| Q36756593 | Insulin resistance and hyperinsulinemia: you can't have one without the other |
| Q44718267 | Insulin resistance and lipid profile in women with polycystic appearing ovaries: implications with regard to polycystic ovary syndrome |
| Q43244951 | Insulin resistance and overweight-obese women with polycystic ovary syndrome |
| Q35087405 | Insulin resistance and polycystic ovary syndrome |
| Q37833622 | Insulin resistance and the long-term consequences of polycystic ovary syndrome |
| Q33569169 | Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications |
| Q34573565 | Insulin resistance in PCOS. |
| Q47118292 | Insulin resistance in nonobese Japanese women with polycystic ovary syndrome is associated with poorer glucose tolerance, delayed insulin secretion, and enhanced insulin response |
| Q35932352 | Insulin resistance in patients with polycystic ovary syndrome |
| Q44739963 | Insulin resistance in polycystic ovary syndrome |
| Q39026021 | Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies |
| Q54248306 | Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. |
| Q35990483 | Insulin resistance in women with hirsutism |
| Q43143954 | Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome |
| Q36690975 | Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. |
| Q55035050 | Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women. |
| Q37565702 | Insulin resistance: the possible link between gestational diabetes mellitus and hypertensive disorders of pregnancy |
| Q46230389 | Insulin response to oral glucose in healthy, lean young women and patients with polycystic ovary syndrome |
| Q35751121 | Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus |
| Q43133486 | Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women |
| Q31028805 | Insulin sensitivity affects corticolimbic brain responses to visual food cues in polycystic ovary syndrome patients |
| Q34530589 | Insulin sensitivity and fertility. |
| Q42499652 | Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia |
| Q35564923 | Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome |
| Q40396673 | Insulin-like growth factors: clinical experience in ovarian function |
| Q36301573 | Insulin-sensitisers in the treatment of polycystic ovary syndrome |
| Q24246323 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome |
| Q24246247 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne, and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome |
| Q36951616 | Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome |
| Q62026014 | Introduction and history of polycystic ovary syndrome |
| Q33538168 | Involvement of growth factors in the pathophysiology of polycystic ovary syndrome |
| Q38771084 | Is foetal hyperexposure to androgens a cause of PCOS? |
| Q36793092 | Is insulin resistance an intrinsic defect in asian polycystic ovary syndrome? |
| Q36673559 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? |
| Q36001614 | Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome? |
| Q51301499 | Is prolactin the missing link in adipose tissue dysfunction of polycystic ovary syndrome patients? |
| Q35510256 | Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. |
| Q33525709 | Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). |
| Q46600474 | Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome |
| Q50048662 | Limitations of insulin resistance assessment in polycystic ovary syndrome. |
| Q63916571 | Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome |
| Q35250192 | Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. |
| Q43054908 | Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months |
| Q45983947 | Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. |
| Q36268785 | Luteal-phase inhibin A and follicular-phase inhibin B levels are not characteristic of patients with an elevated LH-to-FSH ratio |
| Q33904576 | MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. |
| Q21296837 | Mediators of inflammation in polycystic ovary syndrome in relation to adiposity |
| Q37198401 | Menstrual health and the metabolic syndrome in adolescents |
| Q53714426 | Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. |
| Q36987369 | Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome |
| Q59798583 | Metabolic Syndrome and Insulin Resistance Syndrome among Infertile Women with Polycystic Ovary Syndrome: A Cross-Sectional Study from Central Vietnam |
| Q36837099 | Metabolic and Endocrine Characteristics of Indian Women with Polycystic Ovary Syndrome |
| Q59607711 | Metabolic and hormonal aspects of polycystic ovary syndrome: the impact of diet |
| Q37106561 | Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial |
| Q37314250 | Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome |
| Q51590817 | Metabolic approaches to the subclassification of polycystic ovary syndrome. |
| Q38949684 | Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges |
| Q26830631 | Metabolic disturbance in PCOS: clinical and molecular effects on skeletal muscle tissue |
| Q51310893 | Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. |
| Q46952697 | Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors |
| Q97066974 | Metformin during Pregnancy: Effects on Offspring Development and Metabolic Function |
| Q44442558 | Metformin has direct effects on human ovarian steroidogenesis |
| Q33569099 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study |
| Q34348408 | Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects |
| Q48006996 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome |
| Q45153392 | Metformin therapy in women with polycystic ovary syndrome |
| Q24187959 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome |
| Q24241022 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome |
| Q24245869 | Metformin treatment before and during IVF/ICSI in women with polycystic ovarian syndrome |
| Q45254916 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study |
| Q36721550 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review |
| Q22241434 | Metformin: new understandings, new uses |
| Q98224474 | MiR-185-5p Protects Against Angiogenesis in Polycystic Ovary Syndrome by Targeting VEGFA |
| Q36935580 | MicroRNA Species in Follicular Fluid Associating With Polycystic Ovary Syndrome and Related Intermediary Phenotypes. |
| Q35060268 | Modern obstetrical and infertility care may increase the prevalence of disease: an evolutionary concept |
| Q58793563 | Morning blood pressure surge and its relation to insulin resistance in patients of reproductive age with polycystic ovary syndrome |
| Q34554530 | Multiple signal transduction pathways regulate ovarian steroidogenesis |
| Q36152232 | Myo-Inositol Safety in Pregnancy: From Preimplantation Development to Newborn Animals. |
| Q46706686 | Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome |
| Q77694142 | New routes in the polycystic ovary syndrome labyrinth: a way out? |
| Q43220540 | No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia. |
| Q33886930 | Nonalcoholic fatty liver disease and polycystic ovary syndrome |
| Q35506631 | Normal ovarian structure and function with normal glucose tolerance in girls with early treatment of classic congenital adrenal hyperplasia |
| Q41227904 | Nutrition, hormones, and breast cancer: is insulin the missing link? |
| Q64234721 | OUP accepted manuscript |
| Q36644070 | Obesity and Insulin Resistance Are the Main Determinants of Postprandial Lipoprotein Dysmetabolism in Polycystic Ovary Syndrome |
| Q27000954 | Obesity and PCOS: implications for diagnosis and treatment |
| Q90115186 | Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies |
| Q36102086 | Obesity differentially affects phenotypes of polycystic ovary syndrome |
| Q37608349 | Obesity management in women with polycystic ovary syndrome. |
| Q43918197 | Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome |
| Q34536081 | Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome |
| Q39391344 | Obstructive sleep apnoea and polycystic ovary syndrome: A comprehensive review of clinical interactions and underlying pathophysiology |
| Q34301379 | On the association between valproate and polycystic ovary syndrome |
| Q34693587 | Oocyte maturation: the coming of age of a germ cell |
| Q43274978 | Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome. |
| Q40212931 | Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial |
| Q57458409 | Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome |
| Q46916845 | Ovarian dysfunction in peripubertal hyperinsulinemia |
| Q33742664 | Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study |
| Q34696198 | Ovarian steroids: the good, the bad, and the signals that raise them |
| Q46191480 | Ovarian stimulation in obese and non-obese polycystic ovary syndrome using a low-dose step-up regimen with two different starting doses of recombinant follicle-stimulating hormone |
| Q83974732 | Oxidative status and its relation with insulin resistance in young non-obese women with polycystic ovary syndrome |
| Q36508886 | PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity |
| Q38861206 | PHYSIOLOGY AND ENDOCRINOLOGY SYMPOSIUM: Insulin action and lipotoxicity in the development of polycystic ovary syndrome: A review |
| Q30359255 | Pancreatic β-cell dysfunction in polycystic ovary syndrome: role of hyperglycemia-induced nuclear factor-κB activation and systemic inflammation. |
| Q37044215 | Pancreatic β-cell dysfunction in polycystic ovary syndrome: the role of metformin |
| Q30371644 | Parent-of-origin effects on glucose homeostasis in polycystic ovary syndrome. |
| Q46051147 | Participation of ERalpha and ERbeta in glucose homeostasis in skeletal muscle and white adipose tissue |
| Q26738511 | Pathophysiology, risk factors, and screening methods for prediabetes in women with polycystic ovary syndrome |
| Q36943172 | Patterns of LHbetacf among women in health and disease |
| Q35572930 | Peripheral insulin resistance in obese girls with hyperandrogenism is related to oxidative phosphorylation and elevated serum free fatty acids |
| Q34442683 | Pharmacological treatment of obesity in patients with polycystic ovary syndrome |
| Q34024181 | Phosphoprotein enriched in astrocytes (PEA)-15: a potential therapeutic target in multiple disease states |
| Q37250408 | Pioglitazone improves insulin action and normalizes menstrual cycles in a majority of prenatally androgenized female rhesus monkeys |
| Q46470138 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment |
| Q36666354 | Polycystic Ovary Syndrome and Obstructive Sleep Apnea |
| Q35075035 | Polycystic Ovary Syndrome in the Pediatric Population |
| Q27021307 | Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women |
| Q33775146 | Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols |
| Q92437260 | Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls |
| Q43728725 | Polycystic ovarian syndrome (PCOS) and insulin resistance |
| Q34345051 | Polycystic ovarian syndrome in women with epilepsy: a review |
| Q50859636 | Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. |
| Q79148960 | Polycystic ovary syndrome |
| Q80844876 | Polycystic ovary syndrome |
| Q83062366 | Polycystic ovary syndrome |
| Q88098767 | Polycystic ovary syndrome |
| Q37990356 | Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications |
| Q77694096 | Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? |
| Q38380065 | Polycystic ovary syndrome and insulin: our understanding in the past, present and future |
| Q33655236 | Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review |
| Q39455340 | Polycystic ovary syndrome and the risk of obstructive sleep apnea: a meta-analysis and review of the literature |
| Q36622133 | Polycystic ovary syndrome in adolescents: current and future treatment options |
| Q36182504 | Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study |
| Q36920069 | Polycystic ovary syndrome is not associated with genetic variants that mark risk of type 2 diabetes |
| Q40621362 | Polycystic ovary syndrome--long-term metabolic consequences |
| Q39334166 | Polycystic ovary syndrome: Understanding the role of the brain. |
| Q38218598 | Polycystic ovary syndrome: a common hormonal condition with major metabolic sequelae that physicians should know about |
| Q21245262 | Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan |
| Q34100589 | Polycystic ovary syndrome: an endocrine and metabolic disease |
| Q41628765 | Polycystic ovary syndrome: cardiovascular risk factors according to specific phenotypes |
| Q36554676 | Polycystic ovary syndrome: clinical presentation in normal-weight compared with overweight adolescents |
| Q40831696 | Polycystic ovary syndrome: current and future treatment paradigms |
| Q37832125 | Polycystic ovary syndrome: etiology, pathogenesis and diagnosis |
| Q40942933 | Polycystic ovary syndrome: pathophysiology and outcome with in vitro fertilization. |
| Q43621921 | Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow |
| Q77690927 | Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology |
| Q34758467 | Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome |
| Q35896531 | Potential use of durian fruit (Durio zibenthinus Linn) as an adjunct to treat infertility in polycystic ovarian syndrome |
| Q36732197 | Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population |
| Q36862243 | Pregnancy in polycystic ovary syndrome |
| Q36050627 | Preliminary evidence of glycogen synthase kinase 3 beta as a genetic determinant of polycystic ovary syndrome |
| Q77694072 | Premature pubarche, ovarian hyperandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset |
| Q37001625 | Prenatal androgen excess negatively impacts body fat distribution in a nonhuman primate model of polycystic ovary syndrome |
| Q40836292 | Prevalence and possible mechanisms of reactive hypoglycemia in polycystic ovary syndrome. |
| Q38465193 | Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome |
| Q37019757 | Prevalence of hepatic steatosis in women with polycystic ovary syndrome |
| Q51747364 | Prevalence of psychiatric disorders in patients with polycystic ovary syndrome |
| Q46826968 | Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. |
| Q54596205 | Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. |
| Q93173211 | Proteomics analysis of potential serum biomarkers for insulin resistance in patients with polycystic ovary syndrome |
| Q48086732 | Psychiatric comorbidity in women with polycystic ovary syndrome |
| Q35489785 | Puberty and polycystic ovarian syndrome: the insulin/insulin-like growth factor I hypothesis. |
| Q35906966 | Recent advances in the treatment of polycystic ovary syndrome |
| Q45282731 | Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance |
| Q38864973 | Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI. |
| Q78966636 | Relationship between polycystic ovaries, body mass index and insulin resistance |
| Q45168757 | Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome |
| Q44473918 | Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome |
| Q26828765 | Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome |
| Q46979381 | Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up |
| Q35798745 | Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women |
| Q33591300 | Risk of psychiatric disorders following polycystic ovary syndrome: a nationwide population-based cohort study |
| Q26774060 | Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review |
| Q54440177 | Role of GnRH drive in the pathophysiology of polycystic ovary syndrome. |
| Q37355743 | Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity |
| Q88991120 | Role of osteocalcin, tumor necrosis factor-alpha and adiponectin in polycystic ovary syndrome patients with insulin resistance |
| Q37360333 | Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells |
| Q28390200 | Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome |
| Q28360761 | Screening for diabetes in pregnancy |
| Q37097161 | Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease |
| Q51590281 | Sensitivity of plasma insulin levels in obese and non-obese women with functional hyperandrogenism. |
| Q37445314 | Serum C-reactive protein levels in normal-weight polycystic ovary syndrome |
| Q43491849 | Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome |
| Q51312640 | Serum HLA-G levels in women with polycystic ovary syndrome. |
| Q46525200 | Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF. |
| Q50654959 | Serum anti-Müllerian hormone and insulin resistance in the main phenotypes of non-obese polycystic ovarian syndrome women in China. |
| Q33814094 | Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome |
| Q46544840 | Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone |
| Q84328513 | Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome |
| Q51361441 | Serum visfatin levels in women with polycystic ovary syndrome. |
| Q37618529 | Sex differences in the effects of androgens acting in the central nervous system on metabolism |
| Q40418781 | Sex differences, endogenous sex-hormone hormones, sex-hormone binding globulin, and exogenous disruptors in diabetes and related metabolic outcomes |
| Q36931218 | Sex hormone-binding globulin genetic variation: associations with type 2 diabetes mellitus and polycystic ovary syndrome. |
| Q30423117 | Should all women with PCOS be treated for insulin resistance? |
| Q33516103 | Simple modeling allows prediction of steady-state glucose disposal rate from early data in hyperinsulinemic glucose clamps. |
| Q28917062 | Sleep Duration, Exercise, Shift Work and Polycystic Ovarian Syndrome-Related Outcomes in a Healthy Population: A Cross-Sectional Study |
| Q36217225 | Spironolactone for hirsutism in polycystic ovary syndrome |
| Q46426588 | Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. |
| Q35233754 | State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). |
| Q38221447 | Steroidogenesis-adrenal cell signal transduction |
| Q35688517 | Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome |
| Q83170982 | Surgical treatment of obesity |
| Q51372667 | Symmetric dimethylarginine (SDMA) is raised in women with polycystic ovary syndrome: a pilot study. |
| Q35754543 | Systems Genetics Reveals the Functional Context of PCOS Loci and Identifies Genetic and Molecular Mechanisms of Disease Heterogeneity |
| Q38809734 | Testosterone therapy for transgender men. |
| Q35786489 | The Effect of Exercise in PCOS Women Who Exercise Regularly |
| Q35676497 | The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma. |
| Q38597944 | The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis |
| Q41640666 | The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited |
| Q36719299 | The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome |
| Q34190360 | The comparison of insulin resistance frequency in patients with recurrent early pregnancy loss to normal individuals |
| Q39401759 | The contribution of diet, physical activity and sedentary behaviour to body mass index in women with and without polycystic ovary syndrome. |
| Q41690430 | The effect of metformin use on pregnancy rates among polycystic ovary syndrome patients undergoing in vitro fertilization: A retrospective-cohort study |
| Q64111152 | The effectiveness of high intensity intermittent training on metabolic, reproductive and mental health in women with polycystic ovary syndrome: study protocol for the iHIT- randomised controlled trial |
| Q42476947 | The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome |
| Q35181929 | The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study |
| Q36328060 | The effects of old, new and emerging medicines on metabolic aberrations in PCOS. |
| Q46948248 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome |
| Q46669792 | The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome |
| Q37238230 | The efficacy of metformin and clomiphene citrate combination compared with clomiphene citrate alone for ovulation induction in infertile patients with PCOS |
| Q50204098 | The impact of androgen actions in neurons on metabolic health and disease |
| Q45277759 | The impact of insulin resistance on the outcome of laparoscopic ovarian electrocautery in infertile women with the polycystic ovary syndrome |
| Q36971967 | The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials |
| Q51752247 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia |
| Q34026359 | The in utero programming effect of increased maternal androgens and a direct fetal intervention on liver and metabolic function in adult sheep |
| Q40389350 | The link between insulin resistance and hypertension. Effects of antihypertensive and antihyperlipidaemic drugs on insulin sensitivity |
| Q24798425 | The management of infertility associated with polycystic ovary syndrome |
| Q28248914 | The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study |
| Q41952999 | The metabolic syndrome in children and adolescents |
| Q30440354 | The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome |
| Q77694083 | The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies |
| Q64907714 | The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria. |
| Q34163132 | The polycystic ovary syndrome: treatment with insulin sensitizing agents |
| Q34997987 | The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome |
| Q51486636 | The prevalence of polycystic ovaries in Chinese women with a history of gestational diabetes mellitus. |
| Q38231822 | The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome |
| Q44016360 | The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. |
| Q46191484 | The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome |
| Q36259103 | The relationship between epicardial fat tissue thickness and visceral adipose tissue in lean patients with polycystic ovary syndrome |
| Q40196769 | The relationship between metabolic status and levels of adiponectin and ghrelin in lean women with polycystic ovary syndrome |
| Q90177690 | The role of a pulse-based diet on infertility measures and metabolic syndrome risk: protocol of a randomized clinical trial in women with polycystic ovary syndrome |
| Q42488875 | The role of insulin in ovarian size in patients with the polycystic ovary syndrome |
| Q34998688 | The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence |
| Q36799800 | Therapeutic options in the polycystic ovary syndrome |
| Q46104097 | Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome |
| Q43725577 | Tissue insulin sensitivity and body weight in polycystic ovary syndrome |
| Q36098781 | To Assess the Association between Glucose Metabolism and Ectopic Lipid Content in Different Clinical Classifications of PCOS. |
| Q33399651 | Transcriptional profiling with a pathway-oriented analysis identifies dysregulated molecular phenotypes in the endometrium of patients with polycystic ovary syndrome |
| Q42474617 | Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease |
| Q35649437 | Treatment of PCOS with metformin and other insulin-sensitizing agents |
| Q34622523 | Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome |
| Q37764078 | Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? |
| Q42983706 | Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels |
| Q77690932 | Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications |
| Q51492093 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. |
| Q37769526 | Use of metformin in the treatment of polycystic ovary syndrome |
| Q53761370 | Visceral adiposity index levels in overweight and/or obese, and non-obese patients with polycystic ovary syndrome and its relationship with metabolic and inflammatory parameters. |
| Q60047409 | Vitamin D and metabolic disturbances in polycystic ovary syndrome (PCOS): A cross-sectional study |
| Q38072104 | Vitamin D in human reproduction: a narrative review |
| Q50880365 | Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. |
| Q35225508 | World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease: part 4. |
| Q46142884 | World Congress on the Insulin Resistance Syndrome, 2009: Insulin resistance mechanisms, the brain, and insulin resistance in youth and in the polycystic ovary syndrome |
| Q89736882 | Wrist circumference: A new marker for insulin resistance in African women with polycystic ovary syndrome |
| Q51481042 | [Insulin resistance and metabolic profile in lean and overweight/obese polycystic ovary syndrome patients]. |
| Q79566798 | [Polycystic ovary syndrome. Prototype of a cardio-metabolic syndrome] |
Search more.